Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Senolytics as a Novel Treatment for Interstitial Lung Disease in Common Variable Immunodeficiency (CVID)

NCT05593588 is registered in ClinicalTrials.gov with Avni Joshi as lead sponsor.

NCT NCT05593588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05593588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Senolytics as a Novel Treatment for Interstitial Lung Disease in Common Variable Immunodeficiency (CVID)
Lead sponsor
Avni Joshi
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 12, 2023
Completion date
December 31, 2026
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

common variable immunodeficiency, interstitial lung disease due to systemic disease